Therefore, here we focused on alterations in the PI3K/AKT and RAS/MAPK pathways as potential biomarkers of resistance to cetuximab among the 115 HNSCC patients treated with cetuximab at the Curie Institute. This evidence concerns the gene AKT1 and head and neck squamous cell carcinoma.